Every material Form 8-K Exponent filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Exponent reported third-quarter 2025 revenue of $147.1 million, up 8% from a year earlier, and net income of $28.0 million, or $0.55 per diluted share, up from $0.50. The company maintained its full-year revenue outlook, raised its full-year EBITDA margin outlook, and its board declared a $0.30 quarterly dividend and added $100 million to its share repurchase authorization. Nine-month net income and diluted EPS still declined from 2024.
Q3 2025 revenue was $147.1 million, up 8% from $136.3 million; revenues before reimbursements rose 10% to $137.1 million.
Q3 2025 net income was $28.0 million, or $0.55 per diluted share, versus $26.0 million, or $0.50, in Q3 2024.
Nine-month net income fell to $81.2 million, or $1.58 per diluted share, from $85.4 million, or $1.66, a year earlier.
Board declared a $0.30 quarterly dividend payable December 19, 2025 to holders of record December 5, 2025, and added $100 million to the repurchase authority, on top of $21.6 million available as of October 3, 2025.
Exponent reported second quarter 2025 revenues before reimbursements of $132.9 million, approximately flat year over year, and total revenues up 1% to $142.0 million. Net income fell to $26.6 million, or $0.52 per diluted share, from $29.2 million, or $0.57, a year earlier, and the company kept its full-year 2025 guidance while declaring a $0.30 quarterly dividend.
Revenues before reimbursements were $132.9 million, approximately flat versus $132.4 million in Q2 2024; total revenues rose 1% to $142.0 million.
Net income was $26.6 million, or $0.52 per diluted share, versus $29.2 million, or $0.57 per diluted share, in Q2 2024.
Full-year 2025 guidance was maintained: revenues before reimbursements expected to grow in the low single digits, and EBITDA expected at 26.50% to 27.0% of revenues before reimbursements.
Board declared a quarterly cash dividend of $0.30 per share, payable September 19, 2025, to stockholders of record as of September 5, 2025.
Exponent reported first-quarter 2025 revenue of $145.5 million, roughly flat from a year earlier, but net income fell to $26.7 million, or $0.52 per diluted share, from $30.1 million, or $0.59, a year earlier. The company kept its full-year 2025 guidance but expects second-quarter revenues before reimbursements to fall in the low-single digits, and it declared a $0.30 quarterly dividend.
Q1 2025 revenues before reimbursements were $137.4 million, compared with $137.2 million in Q1 2024
Net income was $26.7 million, or $0.52 per diluted share, versus $30.1 million, or $0.59, a year earlier; EBITDA fell to $37.5 million from $40.1 million
For Q2 2025, the company expects revenues before reimbursements to decline in the low-single digits, and full-year 2025 revenues before reimbursements to grow in the low-single digits
Board declared a quarterly cash dividend of $0.30 per share, payable June 20, 2025 to holders of record as of June 6, 2025
Exponent reported fourth-quarter 2024 total revenues of $136.8 million, up 11.3%, and net income of $23.6 million, or $0.46 per diluted share, versus $0.41 a year earlier. The company also raised its quarterly cash dividend from $0.28 to $0.30 per share and guided to first-quarter 2025 revenues down in the low-single digits and full-year 2025 revenues growing in the low-single digits.
Q4 2024 total revenues rose 11.3% to $136.8 million; net income rose to $23.6 million, or $0.46 per diluted share, from $20.9 million, or $0.41
Quarterly dividend increased from $0.28 to $0.30 per share, payable March 21, 2025 to holders of record as of March 7, 2025
Q1 2025 guidance: revenues before reimbursements down in the low-single digits; EBITDA 25.0% to 26.0% of revenues before reimbursements
Full-year 2025 guidance: revenues before reimbursements to grow in the low-single digits; EBITDA 26.25% to 27.0%
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Exponent filing is on SEC EDGAR ↗. 8-K briefs of other companies →